New trial aims to make stem cell transplants safer for blood cancer patients

NCT ID NCT04888741

First seen May 07, 2026 · Last updated Jun 12, 2026 · Updated 9 times

Summary

This study tests two different drug combinations to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body after a stem cell transplant. About 400 adults with blood cancers like leukemia or lymphoma will receive either thymoglobulin or a newer approach using post-transplant cyclophosphamide. The goal is to see which method helps patients live longer without GVHD or cancer relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Addenbrookes Hospital

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Bristol Haematology and Oncology Centre

    RECRUITING

    Bristol, BS2 8ED, United Kingdom

  • Churchill Hospital

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • Derriford Hospital

    RECRUITING

    Plymouth, PL6 8DH, United Kingdom

  • Freeman Hospital

    RECRUITING

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Hammersmith Hospital

    RECRUITING

    London, W12 0HS, United Kingdom

  • King's College Hospital

    RECRUITING

    London, SE5 9RS, United Kingdom

    Contact

  • Manchester Royal Infirmary

    RECRUITING

    Manchester, M13 9WL, United Kingdom

  • Nottingham City Hospital

    RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • Queen Elizabeth Hospital

    RECRUITING

    Birmingham, B15 2GW, United Kingdom

  • Queen Elizabeth Hospital Glasgow

    RECRUITING

    Glasgow, G51 4TF, United Kingdom

    Contact

  • Royal Hallamshire Hospital

    RECRUITING

    Sheffield, S102JF, United Kingdom

  • St Jame's University Hospital

    RECRUITING

    Leeds, LS9 7TF, United Kingdom

  • The Christie

    RECRUITING

    Manchester, M20 3QH, United Kingdom

  • The Royal Marsden Hospital

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

  • University College London Hospital

    RECRUITING

    London, NW1 2BU, United Kingdom

  • University Hospital of Wales

    RECRUITING

    Cardiff, Wales, CF14 4XW, United Kingdom

    Contact

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia Hodgkins lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive Myelodysplastic Syndromes non-Hodgkin lymphoma plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.